(Q38038539)

27 August 2017

Trial designs used to study neuroprotective therapy in Parkinson's disease (English)

1 reference

27 August 2017

1 reference

3

Werner Poewe

1 reference

27 August 2017

4

Olivier Rascol

1 reference

27 August 2017

1

Anthony E Lang

1 reference

27 August 2017

2

Eldad Melamed

1 reference

PubMed ID

22927060

27 August 2017

language of work or name

English

0 references

publication date

23 August 2012

1 reference

27 August 2017

1 reference

27 August 2017

28

1 reference

27 August 2017

1

1 reference

27 August 2017

86-95

1 reference

Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future

27 August 2017

1 reference

Defining disease-modifying therapies for PD--a road map for moving forward

21 January 2018

1 reference

Timing of treatment initiation in Parkinson's disease: a need for reappraisal?

21 January 2018

1 reference

Interpreting the results of Parkinson's disease clinical trials: time for a change

21 January 2018

1 reference

Benign tremulous parkinsonism.

21 January 2018

1 reference

Tremor dominant parkinsonism: Clinical description and LRRK2 mutation screening.

21 January 2018

1 reference

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

21 January 2018

1 reference

TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial

21 January 2018

1 reference

The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations

21 January 2018

1 reference

The clinically important difference on the unified Parkinson's disease rating scale.

21 January 2018

1 reference

UPDRS activity of daily living score as a marker of Parkinson's disease progression

21 January 2018

1 reference

Comparative responsiveness of Parkinson's disease scales to change over time.

21 January 2018

1 reference

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes

21 January 2018

1 reference

The effect of deprenyl and levodopa on the progression of Parkinson's disease

21 January 2018

1 reference

Levodopa and the progression of Parkinson's disease

21 January 2018

1 reference

Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics

21 January 2018

1 reference

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

21 January 2018

1 reference

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

21 January 2018

1 reference

Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study

21 January 2018

1 reference

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

21 January 2018

1 reference

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

21 January 2018

1 reference

Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease

21 January 2018

1 reference

"Disease-modification" trials in Parkinson disease: target populations, endpoints and study design

21 January 2018

1 reference

A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease

21 January 2018

1 reference

A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease

21 January 2018

1 reference

Relationships between age and late progression of Parkinson's disease: a clinico-pathological study.

21 January 2018

1 reference

The progression of pathology in longitudinally followed patients with Parkinson's disease.

21 January 2018

1 reference

Molecular Pathways of Neurodegeneration in Parkinson's Disease

21 January 2018

1 reference

Missing pieces in the Parkinson's disease puzzle

21 January 2018

1 reference

The progression of Parkinson disease: a hypothesis.

21 January 2018

1 reference

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

21 January 2018

1 reference

A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease

21 January 2018

1 reference

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease

21 January 2018

1 reference

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MDS.24997

1 reference

27 August 2017

1 reference

PubMed ID

22927060